SCHEMBL6566442

SCHEMBL6566442

CC(C)c1ccc(Oc2ccc(OC(CCCNCC(=O)O)c3ccccc3)cc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FNTA P49354 1/20 0.47
FNTB P49356 1/20 0.47
SLC6A4 P31645 9/20 0.45
SLC7A5 Q01650 1/20 0.45
GCGR P47871 1/20 0.44
LTA4H P09960 1/20 0.41
SLC6A9 P48067 2/20 0.41
NPC1 O15118 2/20 0.40
CYP2D6 P10635 2/20 0.40
CYP2C19 P33261 2/20 0.40
MTOR P42345 2/20 0.40
RAB9A P51151 2/20 0.40
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
TP53 P04637 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6566281 0.90 SLC6A4 (0.55) FNTAFNTBSLC6A4LTA4HSLC6A9
SCHEMBL6566262 0.90 SLC6A9 (0.49) FNTAFNTBSLC6A4GCGRLTA4H
SCHEMBL6259263 0.88 SLC6A9 (0.49) SLC6A4SLC7A5SLC6A9NPC1CYP2D6
SCHEMBL6566500 0.87 SLC6A9 (0.52) SLC6A4SLC7A5GCGRSLC6A9NPC1
SCHEMBL7214342 0.83 SLC6A4 (0.45) SLC6A4GCGRSLC6A9CYP2D6CYP2C19
SCHEMBL6254431 0.80 SLC7A5 (0.51) SLC6A4SLC7A5SLC6A9NPC1CYP2D6
SCHEMBL6826714 0.79 SLC6A9 (0.48) SLC6A4SLC6A9CYP2D6CYP2C19KDM4E
SCHEMBL7209152 0.79 SLC6A4 (0.51) SLC6A4LTA4HSLC6A9FFAR1
SCHEMBL6259766 0.78 SLC6A4 (0.50) SLC6A4SLC7A5SLC6A9NPC1CYP2D6
SCHEMBL6749875 0.78 SLC6A9 (0.50) SLC6A4SLC7A5SLC6A9NPC1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6784299-B2 CARBOCYCLIC ETHERS SUCH AS (METHYL-(3-(4-PHENOXY-PHENOXY)-3-PHENYL-PROPYL)-AMINO)-ACETIC ACID, USED AS NEUROTRANSMITTER ANTAGONISTS, FOR PROPHYLAXIS OF PSYCHOLOGICAL DISORDERS PFIZER INC. 2004-08-31 US disclosed
EP-1406861-A1 SUBSTITUTED AROMATIC ETHERS AS INHIBITORS OF GLYCINE TRANSPORT Pfizer Products Inc. (US) 2004-04-14 EP disclosed
US-20030208081-A1 Substituted aromatic ethers as inhibitors of glycine transport PFIZER INC. 2003-11-06 US disclosed
US-6566550-B2 Such as (methyl-(3-phenyl-3(4-(3-trifluoromethylphenoxy) phenoxy)propyl)amino)acetic acid for treatment of mental disorders PFIZER INC 2003-05-20 US disclosed
US-20030013887-A1 Such as (methyl-(3-phenyl-3(4-(3-trifluoromethylphenoxy) phenoxy)propyl)amino)acetic acid for treatment of mental disorders PFIZER INC. 2003-01-16 US disclosed
WO-2003000646-A1 SUBSTITUTED AROMATIC ETHERS AS INHIBITORS OF GLYCINE TRANSPORT PFIZER PRODUCTS INC. (US) 2003-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030013887-A1 Such as (methyl-(3-phenyl-3(4-(3-trifluoromethylphenoxy) phenoxy)propyl)amino)acetic acid for treatment of mental disorders SLC1A2, SLC1A1, SLC1A3 FNTA 1222/4885FNTB 1934/4885SLC6A4 21/4885
US-20030208081-A1 Substituted aromatic ethers as inhibitors of glycine transport SLC1A2, SLC1A1, SLC6A1 FNTA 790/4885FNTB 1368/4885SLC6A4 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.